Joe Keegan, CEO of Molecular Devices, greeted analysts at last week’s quarterly conference call by calling the period “the best third quarter in the company’s history.”

Keegan, who has been president and CEO of the 21-year-old company since 1998, was mixed in his outlook, however, noting that the company was surprised by weakness in the drug-discovery market and a slowdown in capital spending for high-dollar tools.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.